Last reviewed · How we verify
ZYN002
At a glance
| Generic name | ZYN002 |
|---|---|
| Also known as | Cannabidiol Transdermal Gel |
| Sponsor | Harmony Biosciences Management, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Open-Label Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents With 22q11.2 Deletion Syndrome (INSPIRE) (PHASE2)
- Drug Interaction Study of ZYN002 Transdermal Gel and Probe Substrates (PHASE1)
- Clinical Study of Cannabidiol in Children, Adolescents, and Young Adults With Fragile X Syndrome (PHASE3)
- Open Label Extension to Assess the Long-Term Safety and Tolerability of ZYN002 in Children and Adolescents With FXS (PHASE2, PHASE3)
- Clinical Study Of caNNabidiol in childrEn and adolesCenTs With Fragile X (CONNECT-FX) (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ZYN002 CI brief — competitive landscape report
- ZYN002 updates RSS · CI watch RSS
- Harmony Biosciences Management, Inc. portfolio CI